William F Doyle sold $933k of NVCR
Executive Chairman at NovoCure Ltd. 71,887 shares at an average of $12.98, traded Mar 3, 2026, filed Mar 5, 2026.
Score components
- +20RoleChair
- +24Trade size$933k at market
- +5Share of holdings soldSold 18% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001194459-26-000001, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 3, 2026 | AGrant or award Ordinary Shares | +200,000 | $0.00 | $0 | 200,000 | Mar 5, 2026 |
| Mar 3, 2026 | AGrant or award Ordinary Shares | +200,284 | $0.00 | $0 | 400,284 | Mar 5, 2026 |
| Mar 3, 2026 | SOpen-market sale Ordinary Shares | -50,557 | $12.79 | $646k | 349,727 | Mar 5, 2026 |
| Mar 3, 2026 | SOpen-market sale Ordinary Shares | -21,330 | $13.43 | $286k | 328,397 | Mar 5, 2026 |
| Mar 3, 2026 | AGrant or award Stock Option (Right to Buy)derivative | +258,445 | $0.00 | $0 | 258,445 | Mar 5, 2026 |
| Mar 3, 2026 | AGrant or award Stock Option (Right to Buy)derivative | +30,072 | $0.00 | $0 | 288,517 | Mar 5, 2026 |
Related signals
Other insiders at NovoCure Ltd and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 39Weak | NovoCure Ltd | Christoph Brackmann Chief Financial Officer | $85k 6,412 shares | -3% | |
| 64Notable | NVCRbuy NovoCure Ltd | Ashley Cordova Chief Executive Officer | $997k 81,550 shares | +23% | |
| 56Moderate | NVCRbuy NovoCure Ltd | Christoph Brackmann Chief Financial Officer | $232k 20,000 shares | +17% | |
| 35Weak | NovoCure Ltd | Jeryl L Hilleman director | $17k 999 shares | -15% | |
| 30Weak | NovoCure Ltd | David Hung director | $17k 999 shares | -8% | |
| 30Weak | NovoCure Ltd | Gabriel Leung director | $17k 999 shares | -1% | |
| 33Weak | NovoCure Ltd | Frank X Leonard EVP, Pres., Novocure Oncology | $528k 30,196 shares | -15% | |
| 30Weak | NovoCure Ltd | Martin J. Madden director | $17k 999 shares | -5% | |
| 30Weak | NovoCure Ltd | W Anthony Vernon director | $17k 999 shares | -1% | |
| 35Weak | NovoCure Ltd | Allyson J Ocean director | $17k 999 shares | -25% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.